• Maintenance of alcohol abstinence; part of a comprehensive alcohol abstinence program.

Contraindicated in:

• Hypersensitivity
• CCr 30 mL/min.

Use Cautiously in:

• CCr 30–50 mL/min (dose ↓ necessary)
• History of depression or suicide attempt
• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Safety and effectiveness not established in children.

CV: palpitations, peripheral edema, syncope, vasodilation.

Derm: rash.

EENT: abnormal vision.

GI: abdominal pain, anorexia, constipation, diarrhea, flatulence, ↑ appetite, nausea, taste perversion, vomiting.

GU: ↓libido, erectile dysfunction.

Metab: weight gain.

MS: arthralgia, back pain, myalgia.

Neuro: tremor , abnormal thinking, anxiety, depression, drowsiness, headache.

Resp: cough, dyspnea, pharyngitis, rhinitis.

Drug-Drug:

• None reported.

(Generic available)

• Delayed-release tablets: 333 mg ;

• PO (Adults): Two 333-mg tablets (666 mg/dose) 3 times daily. Lower doses may be effective in some patients.

• Interacts with and restores balance to CNS glutamate and GABA neurotransmitter systems.

• Continued alcohol abstinence.

Therapeutic Classification: alcohol abuse therapy adjuncts

Pharmacologic Classification: gamma aminobutyric acid gaba analogues

Absorption: 11% absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Not metabolized, excreted mainly unchanged in urine.

Half-life: 20–33 hr.

Campral

(blood levels)

• Instruct patient to take medication as directed, even if relapse occurs. Advise patient to discuss any renewed drinking with health care professional.
• May cause dizziness and changes in vision. Caution patients to avoid driving and other activities requiring alertness until response to medication is known.
• Advise female patients to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
• Encourage patient to continue active counseling and support. Acamprosate helps maintain abstinence only when used as part of a comprehensive psychosocial treatment program.

a-CAM-pro-sate

NDC Code^*

• 0093- Teva Pharmaceuticals USA, Inc.
  • 0093-5352- Acamprosate Calcium
    • 0093-5352-86- 180 TABLET, DELAYED RELEASE in 1 BOTTLE (0093-5352-86)

• 10135- Marlex Pharmaceuticals Inc
  • 10135-636- Acamprosate Calcium
    • 10135-636-32- 180 TABLET, DELAYED RELEASE in 1 BOTTLE (10135-636-32)

• 42291- AvKARE, Inc.
  • 42291-104- Acamprosate Calcium
    • 42291-104-18- 180 TABLET, DELAYED RELEASE in 1 BOTTLE (42291-104-18)

• 60687- American Health Packaging
  • 60687-121- Acamprosate Calcium
    • 60687-121-25- 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-121-25) > 1 TABLET, DELAYED RELEASE in 1 BLISTER PACK (60687-121-95)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-569- acamprosate calcium
    • 68382-569-01- 100 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-01)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-569- acamprosate calcium
    • 68382-569-05- 500 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-05)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-569- acamprosate calcium
    • 68382-569-06- 30 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-06)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-569- acamprosate calcium
    • 68382-569-10- 1000 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-10)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-569- acamprosate calcium
    • 68382-569-16- 90 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-16)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-569- acamprosate calcium
    • 68382-569-28- 180 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-28)

• 68462- Glenmark Pharmaceuticals Inc., USA
  • 68462-435- Acamprosate Calcium
    • 68462-435-11- 10 BLISTER PACK in 1 CARTON (68462-435-11) > 10 TABLET, DELAYED RELEASE in 1 BLISTER PACK

• 68462- Glenmark Pharmaceuticals Inc., USA
  • 68462-435- Acamprosate Calcium
    • 68462-435-18- 180 TABLET, DELAYED RELEASE in 1 BOTTLE (68462-435-18)

• 70771- Cadila Healthcare Limited
  • 70771-1057- acamprosate calcium
    • 70771-1057-0- 1000 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-0)

• 70771- Cadila Healthcare Limited
  • 70771-1057- acamprosate calcium
    • 70771-1057-1- 100 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-1)

• 70771- Cadila Healthcare Limited
  • 70771-1057- acamprosate calcium
    • 70771-1057-3- 30 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-3)

• 70771- Cadila Healthcare Limited
  • 70771-1057- acamprosate calcium
    • 70771-1057-5- 500 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-5)

• 70771- Cadila Healthcare Limited
  • 70771-1057- acamprosate calcium
    • 70771-1057-8- 180 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-8)

• 70771- Cadila Healthcare Limited
  • 70771-1057- acamprosate calcium
    • 70771-1057-9- 90 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-9)